ES2546293T3 - Terapia de inmunización basada en péptidos para el tratamiento de aterosclerosis que fija ApoB como objetivo - Google Patents
Terapia de inmunización basada en péptidos para el tratamiento de aterosclerosis que fija ApoB como objetivo Download PDFInfo
- Publication number
- ES2546293T3 ES2546293T3 ES10181267.5T ES10181267T ES2546293T3 ES 2546293 T3 ES2546293 T3 ES 2546293T3 ES 10181267 T ES10181267 T ES 10181267T ES 2546293 T3 ES2546293 T3 ES 2546293T3
- Authority
- ES
- Spain
- Prior art keywords
- peptide
- peptides
- antibodies
- atherosclerosis
- mda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 61
- 230000003053 immunization Effects 0.000 title description 20
- 238000002649 immunization Methods 0.000 title description 20
- 201000001320 Atherosclerosis Diseases 0.000 title description 11
- 102000018616 Apolipoproteins B Human genes 0.000 title description 2
- 108010027006 Apolipoproteins B Proteins 0.000 title description 2
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical class O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001299 aldehydes Chemical class 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 11
- 210000002376 aorta thoracic Anatomy 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 229940037003 alum Drugs 0.000 description 7
- 210000000709 aorta Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 7
- 210000003291 sinus of valsalva Anatomy 0.000 description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101710176384 Peptide 1 Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 108091005601 modified peptides Proteins 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 210000000702 aorta abdominal Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 101710095342 Apolipoprotein B Proteins 0.000 description 2
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 2
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 2
- 102000013918 Apolipoproteins E Human genes 0.000 description 2
- 108010025628 Apolipoproteins E Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000001765 aortic valve Anatomy 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 102000052249 human APOB Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000003270 subclavian artery Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- -1 OCT compound Chemical class 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 238000010242 retro-orbital bleeding Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0101232A SE0101232D0 (sv) | 2001-04-05 | 2001-04-05 | Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based elisa for determination of immune responses against oxidized low density liprotein |
| SE0101232 | 2001-04-05 | ||
| SE0103754 | 2001-11-09 | ||
| SE0103754A SE0103754L (sv) | 2001-04-05 | 2001-11-09 | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2546293T3 true ES2546293T3 (es) | 2015-09-22 |
Family
ID=26655437
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10181267.5T Expired - Lifetime ES2546293T3 (es) | 2001-04-05 | 2002-04-05 | Terapia de inmunización basada en péptidos para el tratamiento de aterosclerosis que fija ApoB como objetivo |
| ES02714667T Expired - Lifetime ES2317999T3 (es) | 2001-04-05 | 2002-04-05 | Terapia de inmunizacion para el tratamiento de la ateroesclerosis. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02714667T Expired - Lifetime ES2317999T3 (es) | 2001-04-05 | 2002-04-05 | Terapia de inmunizacion para el tratamiento de la ateroesclerosis. |
Country Status (18)
| Country | Link |
|---|---|
| EP (42) | EP1918300A3 (enExample) |
| JP (6) | JP2004529143A (enExample) |
| CN (4) | CN1505525B (enExample) |
| AT (2) | ATE510851T1 (enExample) |
| AU (1) | AU2002246484B8 (enExample) |
| BR (1) | BR0208685A (enExample) |
| CA (3) | CA2606839C (enExample) |
| CY (1) | CY1108817T1 (enExample) |
| DE (1) | DE60230029D1 (enExample) |
| DK (3) | DK2295464T3 (enExample) |
| EE (2) | EE200300487A (enExample) |
| ES (2) | ES2546293T3 (enExample) |
| IL (4) | IL158285A0 (enExample) |
| PL (4) | PL400308A1 (enExample) |
| PT (1) | PT1383526E (enExample) |
| RU (1) | RU2296582C2 (enExample) |
| SE (1) | SE0103754L (enExample) |
| WO (1) | WO2002080954A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0103754L (sv) * | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
| US20030105003A1 (en) | 2001-04-05 | 2003-06-05 | Jan Nilsson | Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| CA2460787A1 (en) | 2001-09-28 | 2003-04-03 | Esperion Therapeutics, Inc. | Prevention and treatment of restenosis by local administration of drug |
| SE0302312D0 (sv) | 2002-10-04 | 2003-08-27 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
| AU2003267905B2 (en) * | 2002-10-04 | 2009-02-05 | Biolnvent International Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
| SE0302422D0 (sv) * | 2003-09-11 | 2003-09-11 | Forskarpatent I Syd Ab | Peptide-based immunization therapy for treatment of atherosclerosis |
| SE0400683D0 (sv) * | 2004-03-19 | 2004-03-19 | Forskarpatent I Syd Ab | Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis |
| EP1732383A4 (en) | 2004-04-06 | 2007-05-02 | Cedars Sinai Medical Center | PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH RECOMBINANT ADENO ASSOCIATED VIRUS VECTORS THAT CODE APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO |
| CA2776927C (en) * | 2004-04-15 | 2014-08-12 | Athera Biotechnologies Ab | Phosphorylcholine conjugates and corresponding antibodies |
| EP1676602A1 (en) * | 2005-01-04 | 2006-07-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Continuous administration of epitopes derived from protein present in atherosclerotic plaque for the treatment of atherosclerosis |
| GB0517878D0 (en) | 2005-09-02 | 2005-10-12 | Bioinvent Int Ab | Immunotherapeutic treatment |
| BRPI0720215A2 (pt) * | 2006-12-22 | 2013-12-24 | Abbott Lab | Painel de doença autoimune cardiovascular e métodos de usar o mesmo. |
| WO2008104194A1 (en) * | 2007-02-28 | 2008-09-04 | Bioinvent International Ab | Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques |
| PE20090188A1 (es) | 2007-03-15 | 2009-03-20 | Novartis Ag | Compuestos heterociclicos como moduladores de la senda de hedgehog |
| DK2538222T3 (da) * | 2007-11-05 | 2021-11-15 | Nordic Bioscience As | Biokemiske markører til cvd-risikovurdering |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| EP2319924B1 (en) * | 2008-08-15 | 2016-03-09 | Fujikura Kasei Co., Ltd. | Polypeptide marker for diagnosis of arteriosclerosis, method for detection of arteriosclerosis by using the maker or the like, and kit for diagnosis of arteriosclerosis |
| AU2010319323B2 (en) * | 2009-11-14 | 2015-01-15 | Cardiovax, Llc | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis |
| US8506964B2 (en) | 2010-02-05 | 2013-08-13 | Cardiovax, Llc | Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis |
| WO2012024309A2 (en) | 2010-08-18 | 2012-02-23 | Cedars-Sinai Medical Center | Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer |
| RU2013126888A (ru) | 2010-11-12 | 2014-12-20 | Седарс-Синаи Медикал Сентер | ИММУНОМОДУЛИРУЮЩИЕ КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ, СОДЕРЖАЩИЕ ИММУНОГЕННЫЕ ФРАГМЕНТЫ АроВ100 |
| CA2817543A1 (en) | 2010-11-12 | 2012-06-07 | Cedars-Sinai Medical Center | Immunomodulatory methods and systems for treatment and/or prevention of hypertension |
| CN103501806A (zh) * | 2010-11-12 | 2014-01-08 | 赛达斯西奈医疗中心 | 用于治疗和/或预防动脉瘤的免疫调节方法和系统 |
| SI2742068T1 (sl) | 2011-08-09 | 2019-08-30 | Athera Biotechnologies Ab | Nova protitelesa proti fosforilholinu |
| CA2843960C (en) | 2011-08-09 | 2020-09-15 | Athera Biotechnologies Ab | Antibodies binding to phosphorylcholine (pc) and/or pc conjugates |
| RU2495048C1 (ru) * | 2012-04-18 | 2013-10-10 | Андрей Валентинович Исаев | Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов |
| CN104768970B (zh) | 2012-11-06 | 2019-11-15 | 日内瓦大学 | 模拟肽 |
| CN103520713B (zh) * | 2013-10-16 | 2015-10-28 | 西北农林科技大学 | 一种ApoB100酵母重组疫苗及其制备方法和应用 |
| CN103860470A (zh) * | 2014-03-05 | 2014-06-18 | 贵州中泰生物科技有限公司 | 一种口服高密度脂蛋白脂质体的制备方法 |
| CN105315364B (zh) * | 2014-06-17 | 2018-09-18 | 广州文瑞生物科技有限公司 | 胶原蛋白vi疫苗预防动脉粥样硬化 |
| CN114085283A (zh) * | 2015-05-19 | 2022-02-25 | 拉·约拉过敏反应及免疫医学研究所 | 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途 |
| US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
| CN108478817B (zh) * | 2018-03-16 | 2020-10-27 | 北京大学 | 一种动脉粥样硬化检测试剂及其制备方法 |
| US11690912B2 (en) | 2018-05-29 | 2023-07-04 | Abcentra, Llc | Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody |
| EP3801590A4 (en) | 2018-05-29 | 2022-03-16 | Abcentra, LLC | COMPOSITIONS AND METHODS FOR THE TREATMENT OF Psoriasis |
| CN115025210B (zh) * | 2021-03-05 | 2025-09-05 | 香港中文大学 | 减少动脉粥样硬化进展的肽疫苗组合物和药物制剂 |
| CN115025211A (zh) * | 2021-11-02 | 2022-09-09 | 南京理工大学 | 用于动脉粥样硬化治疗的纳米疫苗及其制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970144A (en) | 1984-12-31 | 1990-11-13 | International Genetic Engineering | Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use |
| US5972890A (en) * | 1988-05-02 | 1999-10-26 | New England Deaconess Hospital Corporation | Synthetic peptides for arterial imaging |
| WO1993018067A1 (en) * | 1992-03-06 | 1993-09-16 | Abbott Laboratories | Immunocapture assay for direct quantitation of specific lipoprotein cholesterol levels |
| WO1994000592A1 (en) * | 1992-06-26 | 1994-01-06 | Exocell, Inc. | Monoclonal antibodies against glycated low density lipoprotein |
| CA2142007C (en) * | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
| KR0185334B1 (ko) | 1995-11-02 | 1999-04-01 | 김은영 | 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이 |
| GB9609702D0 (en) * | 1996-05-09 | 1996-07-10 | Royal Free Hosp School Med | Anticoagulant peptides |
| GB9620153D0 (en) * | 1996-09-27 | 1996-11-13 | Univ Strathclyde | Non-naturally occurring lipoprotein particle |
| GB9705831D0 (en) * | 1997-03-20 | 1997-05-07 | Univ Leicester | Oxidised ldl |
| US6635623B1 (en) * | 1997-06-13 | 2003-10-21 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
| US6225070B1 (en) | 1997-08-07 | 2001-05-01 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma |
| US6156315A (en) * | 1997-10-10 | 2000-12-05 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting the binding of low density lipoprotein to blood vessel matrix |
| EP0911344B1 (en) * | 1997-10-15 | 2004-03-03 | Fujirebio Inc. | Anti-Apo-B-48 monoclonal antibody, hybridoma, and methods of use |
| CA2323056A1 (en) * | 1998-03-10 | 1999-09-16 | Regents Of The University Of California | Methods and tools for identifying compounds which modulate atherosclerosis by impacting ldl-proteoglycan binding |
| WO2000002920A1 (en) * | 1998-07-13 | 2000-01-20 | University Of Otago | Inhibition of lipoprotein formation |
| IL126447A (en) * | 1998-10-04 | 2004-09-27 | Vascular Biogenics Ltd | An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis |
| EP1224461B1 (en) * | 1999-10-26 | 2011-04-20 | The Regents of The University of California | Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| GB2373500B (en) * | 2000-02-04 | 2004-12-15 | Aeomica Inc | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| US20030165503A1 (en) * | 2000-03-03 | 2003-09-04 | Jean-Charles Fruchart | Vaccine for the treatment of atherosclerosis |
| SE0000855D0 (sv) * | 2000-03-15 | 2000-03-15 | Karolinska Innovations Ab | Antigenic composition useful as a vaccine against atherosclerosis |
| GB0017641D0 (en) * | 2000-07-18 | 2000-09-06 | Medigene Oy | Peptides and their use |
| EP1186299A1 (en) * | 2000-09-12 | 2002-03-13 | Universitair Medisch Centrum Utrecht | The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system |
| EP1592445A4 (en) * | 2000-10-25 | 2007-01-10 | Vincent Agnello | METHOD FOR INHIBITING HEPATITIS C VIRUS (HCV) INFECTION AND OTHER FLAVIRIDAE / I FAMILY VIRUSES, AND OTHER BLOODY-VIRUSES COMPLEXING WITH LOW OR VERY LOW DENSITY LIPOPROTEIN DENSITY, BY PREVENTING VIRAL ENTRY IN A CELL |
| WO2002042426A2 (en) * | 2000-11-10 | 2002-05-30 | University Of Utah Research Foundation | Carrier system for specific artery wall gene delivery |
| SE0103754L (sv) * | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
| MXPA03010456A (es) * | 2001-05-15 | 2004-12-06 | Japan Inmunores Lab Co Ltd | Peptidos reactivos a lipoproteina de alta densidad. |
| WO2003007689A2 (en) * | 2001-07-20 | 2003-01-30 | Eidgenoessische Technische Hochschule Zurich (Ethz) | Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
-
2001
- 2001-11-09 SE SE0103754A patent/SE0103754L/xx not_active Application Discontinuation
-
2002
- 2002-04-05 EP EP07119130A patent/EP1918300A3/en not_active Withdrawn
- 2002-04-05 CN CN028089405A patent/CN1505525B/zh not_active Expired - Fee Related
- 2002-04-05 EP EP10180176A patent/EP2305708A1/en not_active Withdrawn
- 2002-04-05 ES ES10181267.5T patent/ES2546293T3/es not_active Expired - Lifetime
- 2002-04-05 EP EP10181213A patent/EP2289930A1/en not_active Withdrawn
- 2002-04-05 EP EP10180193A patent/EP2289917A1/en not_active Withdrawn
- 2002-04-05 DK DK10181267.5T patent/DK2295464T3/en active
- 2002-04-05 EP EP10180156A patent/EP2295459A1/en not_active Withdrawn
- 2002-04-05 EP EP10180091A patent/EP2305706A1/en not_active Withdrawn
- 2002-04-05 RU RU2003132443/15A patent/RU2296582C2/ru active
- 2002-04-05 BR BR0208685-9A patent/BR0208685A/pt not_active Application Discontinuation
- 2002-04-05 JP JP2002578993A patent/JP2004529143A/ja not_active Withdrawn
- 2002-04-05 EP EP10180823A patent/EP2289919A1/en not_active Withdrawn
- 2002-04-05 ES ES02714667T patent/ES2317999T3/es not_active Expired - Lifetime
- 2002-04-05 PL PL400308A patent/PL400308A1/pl unknown
- 2002-04-05 PL PL02367301A patent/PL367301A1/xx unknown
- 2002-04-05 EP EP10180172A patent/EP2289915A1/en not_active Withdrawn
- 2002-04-05 AU AU2002246484A patent/AU2002246484B8/en not_active Expired
- 2002-04-05 PT PT02714667T patent/PT1383526E/pt unknown
- 2002-04-05 EP EP10180838A patent/EP2289923A1/en not_active Withdrawn
- 2002-04-05 EP EP10180828A patent/EP2289921A1/en not_active Withdrawn
- 2002-04-05 EP EP10181263A patent/EP2295463A1/en not_active Withdrawn
- 2002-04-05 EP EP08167533A patent/EP2147930A3/en not_active Withdrawn
- 2002-04-05 AT AT08151489T patent/ATE510851T1/de not_active IP Right Cessation
- 2002-04-05 CN CN201210322795.9A patent/CN103122031B/zh not_active Expired - Lifetime
- 2002-04-05 EP EP10180162.9A patent/EP2295460B1/en not_active Expired - Lifetime
- 2002-04-05 EP EP10181167A patent/EP2289925A1/en not_active Withdrawn
- 2002-04-05 EP EP10181188A patent/EP2289927A1/en not_active Withdrawn
- 2002-04-05 EP EP10180826A patent/EP2289920A1/en not_active Withdrawn
- 2002-04-05 EP EP02714667A patent/EP1383526B1/en not_active Expired - Lifetime
- 2002-04-05 EP EP10180026A patent/EP2295457A1/en not_active Withdrawn
- 2002-04-05 EP EP10180835A patent/EP2289922A1/en not_active Withdrawn
- 2002-04-05 EP EP08167531A patent/EP2147929A3/en not_active Ceased
- 2002-04-05 AT AT02714667T patent/ATE415423T1/de active
- 2002-04-05 EP EP10180099A patent/EP2295458A1/en not_active Withdrawn
- 2002-04-05 EP EP10181227A patent/EP2289932A1/en not_active Withdrawn
- 2002-04-05 EE EEP200300487A patent/EE200300487A/xx unknown
- 2002-04-05 IL IL15828502A patent/IL158285A0/xx unknown
- 2002-04-05 PL PL391615A patent/PL217858B1/pl unknown
- 2002-04-05 CA CA2606839A patent/CA2606839C/en not_active Expired - Lifetime
- 2002-04-05 EP EP10180168A patent/EP2295461A1/en not_active Withdrawn
- 2002-04-05 EP EP10180199A patent/EP2289918A1/en not_active Withdrawn
- 2002-04-05 EP EP10181267.5A patent/EP2295464B1/en not_active Expired - Lifetime
- 2002-04-05 EP EP10180106A patent/EP2289912A1/en not_active Withdrawn
- 2002-04-05 EP EP10180845A patent/EP2289924A1/en not_active Withdrawn
- 2002-04-05 EP EP10181245A patent/EP2289933A1/en not_active Withdrawn
- 2002-04-05 PL PL385189A patent/PL215401B1/pl unknown
- 2002-04-05 WO PCT/SE2002/000679 patent/WO2002080954A1/en not_active Ceased
- 2002-04-05 EP EP10180115A patent/EP2305707A1/en not_active Withdrawn
- 2002-04-05 EP EP10181253.5A patent/EP2289934B1/en not_active Expired - Lifetime
- 2002-04-05 CA CA2443223A patent/CA2443223C/en not_active Expired - Lifetime
- 2002-04-05 EP EP08158141A patent/EP2147928A3/en not_active Withdrawn
- 2002-04-05 EP EP10181217A patent/EP2289931A1/en not_active Withdrawn
- 2002-04-05 EP EP10181203A patent/EP2289929A1/en not_active Withdrawn
- 2002-04-05 EP EP10180184A patent/EP2295462A1/en not_active Withdrawn
- 2002-04-05 EP EP08167532A patent/EP2147680A3/en not_active Withdrawn
- 2002-04-05 EP EP08151489A patent/EP2006301B1/en not_active Expired - Lifetime
- 2002-04-05 DK DK08151489.5T patent/DK2006301T3/da active
- 2002-04-05 EP EP10181273A patent/EP2289935A1/en not_active Withdrawn
- 2002-04-05 EP EP10180188A patent/EP2289916A1/en not_active Withdrawn
- 2002-04-05 EP EP10181173A patent/EP2289926A1/en not_active Withdrawn
- 2002-04-05 CA CA2827167A patent/CA2827167A1/en not_active Abandoned
- 2002-04-05 EP EP10180111A patent/EP2289914A1/en not_active Withdrawn
- 2002-04-05 EP EP10180109A patent/EP2289913A1/en not_active Withdrawn
- 2002-04-05 CN CN2007101953989A patent/CN101284874B/zh not_active Expired - Lifetime
- 2002-04-05 EP EP10181196A patent/EP2289928A1/en not_active Withdrawn
- 2002-04-05 DK DK02714667T patent/DK1383526T3/da active
- 2002-04-05 DE DE60230029T patent/DE60230029D1/de not_active Expired - Lifetime
- 2002-04-05 EE EEP200700052A patent/EE200700052A/xx unknown
- 2002-04-05 CN CNA2009100095655A patent/CN101486766A/zh active Pending
-
2003
- 2003-10-07 IL IL158285A patent/IL158285A/en active IP Right Grant
-
2007
- 2007-12-20 IL IL188286A patent/IL188286A0/en unknown
-
2008
- 2008-01-25 JP JP2008015545A patent/JP2008169215A/ja not_active Withdrawn
- 2008-11-18 IL IL195356A patent/IL195356A0/en unknown
-
2009
- 2009-02-24 CY CY20091100202T patent/CY1108817T1/el unknown
- 2009-06-02 JP JP2009133383A patent/JP5270456B2/ja not_active Expired - Fee Related
-
2010
- 2010-10-26 JP JP2010239478A patent/JP5300820B2/ja not_active Expired - Lifetime
- 2010-10-26 JP JP2010239477A patent/JP5300819B2/ja not_active Expired - Lifetime
-
2013
- 2013-02-25 JP JP2013034312A patent/JP5613890B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2546293T3 (es) | Terapia de inmunización basada en péptidos para el tratamiento de aterosclerosis que fija ApoB como objetivo | |
| US7528225B2 (en) | Peptide epitopes of apolipoprotein B | |
| ES2367146T3 (es) | Terapia de inmunización basadas en péptidos para el tratamiento de aterosclerosis. |